The stock of Spruce Biosciences Inc (NASDAQ: SPRB) has decreased by -4.75 when compared to last closing price of 0.38.Despite this, the company has seen a loss of -1.41% in its stock price over the last five trading days. zacks.com reported 2024-12-13 that Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is It Worth Investing in Spruce Biosciences Inc (NASDAQ: SPRB) Right Now?
Moreover, the 36-month beta value for SPRB is 2.39. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for SPRB is 28.49M and currently, short sellers hold a 0.38% of that float. On January 20, 2025, SPRB’s average trading volume was 601.00K shares.
SPRB’s Market Performance
SPRB’s stock has seen a -1.41% decrease for the week, with a -6.15% drop in the past month and a -29.72% fall in the past quarter. The volatility ratio for the week is 7.69%, and the volatility levels for the past 30 days are at 7.51% for Spruce Biosciences Inc. The simple moving average for the past 20 days is -7.46% for SPRB’s stock, with a -33.75% simple moving average for the past 200 days.
Analysts’ Opinion of SPRB
RBC Capital Mkts gave a rating of “Sector Perform” to SPRB, setting the target price at $2 in the report published on March 14th of the previous year.
SPRB Trading at -20.21% from the 50-Day Moving Average
After a stumble in the market that brought SPRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.87% of loss for the given period.
Volatility was left at 7.51%, however, over the last 30 days, the volatility rate increased by 7.69%, as shares sank -9.79% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -31.81% lower at present.
During the last 5 trading sessions, SPRB fell by -1.41%, which changed the moving average for the period of 200-days by -57.03% in comparison to the 20-day moving average, which settled at $0.3942. In addition, Spruce Biosciences Inc saw -13.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SPRB starting from Novo Holdings A/S, who sale 465,021 shares at the price of $0.75 back on Mar 21 ’24. After this action, Novo Holdings A/S now owns 2,550,000 shares of Spruce Biosciences Inc, valued at $350,951 using the latest closing price.
Novo Holdings A/S, the 10% Owner of Spruce Biosciences Inc, sale 842,020 shares at $0.77 during a trade that took place back on Mar 18 ’24, which means that Novo Holdings A/S is holding 3,968,000 shares at $647,008 based on the most recent closing price.
Stock Fundamentals for SPRB
Current profitability levels for the company are sitting at:
- -6.09 for the present operating margin
- -0.14 for the gross margin
The net margin for Spruce Biosciences Inc stands at -5.55. The total capital return value is set at -0.81. Equity return is now at value -57.55, with -44.28 for asset returns.
Based on Spruce Biosciences Inc (SPRB), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -14.4. The debt to equity ratio resting at 0.06. The interest coverage ratio of the stock is -121.12.
Currently, EBITDA for the company is -47.37 million with net debt to EBITDA at 1.46. When we switch over and look at the enterprise to sales, we see a ratio of -5.88. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.36.
Conclusion
To wrap up, the performance of Spruce Biosciences Inc (SPRB) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
